Conference Coverage
Conference Coverage
CPAP not only solution for sleep apnea
Most commonly, obstructive sleep apnea involves the cessation or significant decrease in airflow while sleeping.
Conference Coverage
Donanemab bests aducanumab in head-to-head Alzheimer’s trial
Nearly 40% of patients treated with donanemab had amyloid clearance at 6 months compared with less than 2% of those who received aducanumab.
Conference Coverage
New hope for adult children with ‘failure to launch’ syndrome
The novel program focuses on reducing parents’ family accommodation, a descriptor for a child’s excessive dependence on their parents to help them...
Conference Coverage
Cautious optimism for new Alzheimer’s disease biomarkers and treatments, expert says
“The greatest challenge is cost, as blood-based biomarkers are not currently covered by insurance and still rather costly.”
Conference Coverage
High-dose vitamin D and MS relapse: New phase 3 data
The study found no benefit, but was the exclusion criteria to blame?
Conference Coverage
Machine learning can predict primary progressive MS progression
The model, which is clinically viable even as it is still evolving, predicts disability progression with an accuracy of approximately 70%.
Conference Coverage
Noninvasive testing in midlife flags late-onset epilepsy risk
The study could help identify at-risk individuals years before symptoms of epilepsy appear.
Conference Coverage
Therapy to reverse muscle dystrophies shows promise
Interim study data showed rapid reductions in multiple biomarkers of muscle injury, reductions in anti-inflammatory markers, proteomic changes...
Conference Coverage
Atogepant prevents episodic migraine in some difficult-to-treat cases
Initial results showed patients receiving oral atogepant had significantly fewer mean monthly migraine days, achieved 50% or greater reduction in...
Conference Coverage
Ablation for atrial fibrillation may protect the aging brain
Adults who had previously undergone catheter ablation were significantly less likely to be cognitively impaired during the 2-year study period,...
Conference Coverage
Phase 3 study of new levodopa/carbidopa delivery system meets all efficacy endpoints
The subcutaneous infusion system improved ON time without troublesome dyskinesias while improving symptoms according to ratings from both patients...